Cardiol Therapeutics Files Material Change Report
Ticker: CRDL · Form: 6-K · Filed: Oct 27, 2025 · CIK: 1702123
Sentiment: neutral
Topics: material-change, regulatory-filing, biotech
Related Tickers: CRDL
TL;DR
Cardiol Therapeutics (CRDL) filed a 6-K with a Material Change Report on Oct 27, 2025. Watch for updates.
AI Summary
Cardiol Therapeutics Inc. filed a Form 6-K on October 27, 2025, reporting a Material Change Report dated October 27, 2025. The company, based in Oakville, Ontario, Canada, is involved in the biological products sector.
Why It Matters
This filing indicates a significant update or event for Cardiol Therapeutics, which could impact its business operations or stock performance.
Risk Assessment
Risk Level: low — The filing is a routine report of a material change, not an indication of immediate financial distress or significant positive news.
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- October 27, 2025 (date) — Filing and Report Date
- Oakville, Ontario, Canada (location) — Company Address
FAQ
What is the nature of the Material Change Report filed by Cardiol Therapeutics?
The filing itself is the Material Change Report dated October 27, 2025, but the specific details of the change are not provided within this Form 6-K header.
When was this Form 6-K filed?
The Form 6-K was filed on October 27, 2025.
What is Cardiol Therapeutics' primary business sector?
Cardiol Therapeutics Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
Where is Cardiol Therapeutics headquartered?
Cardiol Therapeutics Inc. is headquartered at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5.
Does Cardiol Therapeutics file annual reports under Form 20-F or Form 40-F?
Cardiol Therapeutics files annual reports under Form 40-F.
Filing Stats: 161 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-10-27 12:02:41
Filing Documents
- form6k.htm (6-K) — 5KB
- exhibit99-1.htm (EX-99.1) — 35KB
- exhibit99-1xm001.jpg (GRAPHIC) — 8KB
- exhibit99-1xm002.jpg (GRAPHIC) — 8KB
- 0001062993-25-016296.txt ( ) — 62KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 27, 2025 By: /s/ Chris Waddick Chris Waddick Title: Chief Financial Officer